Diagnostic and Patient Management Study (DPMS)

Current status:

• Eight sites across Europe:
  • UNIGE – Geneva (Switzerland) 
  • VUmc – Amsterdam (Netherlands) 
  • CHUT – Toulouse (France) 
  • UKK – Cologne (Germany)
  • BBRC – Barcelona (Spain)
  • UCL – London (UK)
  • CHUV – Lausanne (Switzerland) 
  • KI – Stockholm (Sweden)
• 844 participants recruited in AMYPAD DPMS (854 scans performed including 114 repeated scans).
• Recruitment ended on 30th October 2020.
• All scans and visits were completed by end of June 2021.
• All sites have been monitored and closed.

Prognostic and Natural History Study (PNHS)

Current status:

• 6 activated Wave-1 sites: VUMC, UEDIN, BBRC, CHUT, UNIGE, KI
  
• 11 activated Wave-2 sites: Montpellier (France), NHS TAYSIDE (UK), Paris la Pitié Salpêtrière (France), UZ Leuven (Belgium),  Paris Nord (France), Nantes (France), CITA (Spain), Fundacio ACE (Spain), Lille (France), UC Louvain (Belgium), UGOT (Sweden)
  
• To date 6 sites are done with the recruitment and scanning of their participants (UEDIN, Tayside, CHUT, Nantes, Paris la Pitié and Fundació ACE)
• 10 Parent Cohorts actively enrolling into AMYPAD PNHS (EPAD LCS, EMIF-AD, ALFA+, FACEHBI, FPACK, UCL, Microbiota, 90+, H70, AMYPAD DPMS-VUmc)
• 1.284 participants recruited of which 1.354 (1138 baseline + 216 EPAD FU) have been scanned.
  
• Recruitment ongoing. The Last Patient In (LPI) is on the 30^th of April 2022.

Updated 29 April 2022